Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease

NCT07625384 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Still Disease

Interventions

DRUG: Placebo
BIOLOGICAL: Goflikicept
BIOLOGICAL: Olokizumab

Sponsor

R-Pharm International, LLC